H. Hwangbo

发表

Additivity predicts the efficacy of most approved combination therapies for advanced cancer

S. Patterson, A. Palmer, D. Plana, 2022, medRxiv.

Predictable clinical benefits without synergy in trials of combination therapies with immune checkpoint inhibitors

P. Sorger, Haeun Hwangbo, A. Palmer, 2021 .

Combinatorial benefit without synergy in recent clinical trials of immune checkpoint inhibitors

P. Sorger, A. Palmer, B. Izar, 2020 .

Aberrant Transcript Usage Is Associated with Homologous Recombination Deficiency and Predicts Therapeutic Response

Jae-Weon Kim, J. Choi, Sinae Kim, 2021, Cancer Research.

Predictable Clinical Benefits without Evidence of Synergy in Trials of Combination Therapies with Immune-Checkpoint Inhibitors

P. Sorger, A. Palmer, B. Izar, 2022, Clinical Cancer Research.

Computational inference of cancer-specific vulnerabilities in clinical samples

Min Kyung Sung, S. Ahn, J. Choi, 2020, Genome Biology.

Computational inference of cancer-specific vulnerabilities in clinical samples

Min Kyung Sung, S. Ahn, J. Choi, 2020, Genome Biology.

An RNA Damage Response Network Mediates the Lethality of 5-FU in Clinically Relevant Tumor Types

Jonathan M. Hernandez, Karl A. Merrick, M. Yaffe, 2023, bioRxiv.

CLINICAL CANCER RESEARCH | TRANSLATIONAL CANCER MECHANISMS AND THERAPY PredictableClinical Benefitswithout Evidenceof Synergy in Trials of Combination Therapies with Immune-Checkpoint Inhibitors

P. Sorger, A. Palmer, B. Izar, 2021 .

Aberrant transcript usage induces homologous recombination deficiency and predicts therapeutic responses

J. Choi, Min Ji Park, Suhwan Chang, 2021, medRxiv.